Ongoing Developments and Clinical Progress in Drug-Loaded Red Blood Cell Technologies

Engineered red blood cells (RBCs) appear to be a promising method for therapeutic drug and protein delivery. With a number of agents in clinical trials (e.g., dexamethasone 21-phosphate in ataxia telangiectasia, asparaginase in pancreatic cancer/acute lymphoblastic leukemia, thymidine phosphorylase...

Full description

Saved in:
Bibliographic Details
Published in:BioDrugs : clinical immunotherapeutics, biopharmaceuticals, and gene therapy biopharmaceuticals, and gene therapy, 2020-06, Vol.34 (3), p.265-272
Main Authors: Rossi, Luigia, Pierigè, Francesca, Aliano, Mattia Paolo, Magnani, Mauro
Format: Article
Language:English
Subjects:
Acute lymphoblastic leukemia
Antibodies
Asparaginase
Asparaginase - administration & dosage
Ataxia
Ataxia telangiectasia
Biomedical and Life Sciences
Biomedicine
Blood
Cancer Research
Cancer therapies
Cell Engineering
Chemotherapy
Circulatory system
Clinical trials
Clinical Trials as Topic
Dexamethasone
Dexamethasone - administration & dosage
Drug Carriers
Drug dosages
Erythrocytes
Humans
Leading
Leading Article
Leukemia
Lymphatic leukemia
Mitochondria
Molecular Medicine
Pancreatic cancer
Pharmacotherapy
Phenylalanine Ammonia-Lyase - administration & dosage
Phenylketonuria
Phosphorylase
Thymidine
Thymidine phosphorylase
Thymidine Phosphorylase - administration & dosage
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Engineered red blood cells (RBCs) appear to be a promising method for therapeutic drug and protein delivery. With a number of agents in clinical trials (e.g., dexamethasone 21-phosphate in ataxia telangiectasia, asparaginase in pancreatic cancer/acute lymphoblastic leukemia, thymidine phosphorylase in mitochondrial neurogastrointestinal encephalomyopathy, RTX-134 in phenylketonuria, etc.), this leading article summarizes the ongoing efforts in developing these agents, focuses on the clinical progress, and provides a brief background into engineered RBCs and the different ways in which they can be exploited for therapeutic/diagnostic purposes. References to available data on safety, efficacy, and tolerability are reported. Due to the continuous progress in this field, the information is updated as of January 2020 from databases, websites, and press releases of the involved companies and information that is in the public domain.
ISSN:1173-8804
1179-190X
DOI:10.1007/s40259-020-00415-0